Dana-Farber Cancer Institute is rolling out Solavia Decision Suite, a next-generation oncology decision support platform built in partnership with NYU Langone Health. Designed to tackle one of oncology's biggest pain points — the sheer pace of new drug approvals, trial results, and evolving guidelines — Solavia embeds evidence-based treatment pathways directly into the Epic EHR, giving clinicians context-specific guidance based on a patient's disease, stage, and prior treatment history.

The platform draws on more than a decade of Dana-Farber's clinical pathway development, with recommendations continuously reviewed and updated by expert committees. NYU Langone launched Solavia internally in June and announced commercial availability in July; Dana-Farber will begin its own phased rollout in September. Importantly, the tool is designed to complement, not replace, clinical judgment — physicians remain in the driver's seat.

Key Takeaways:

• Solavia is embedded within Epic EHR, delivering guidance at the point of care without disrupting workflow
• Treatment pathways are continuously updated by Dana-Farber expert committees as new evidence emerges
• The platform is commercially available and represents a scalable model for extending academic cancer center expertise more broadly

Why it matters: As cancer treatment grows more complex, community oncologists often lack access to the subspecialty depth available at major academic centers. Solavia offers a scalable way to close that gap — potentially improving treatment decisions for patients well beyond Dana-Farber's walls.